Gliadel Wafer Implantation Combined With Standard Radiotherapy and Concurrent Followed by Adjuvant Temozolomide for Treatment of Newly Diagnosed High-Grade Glioma: A Systematic Literature Review by Ashby, Lynn S. et al.
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center 
Barrow - St. Joseph's Scholarly Commons 
Neurology 
2016 
Gliadel Wafer Implantation Combined With Standard Radiotherapy 
and Concurrent Followed by Adjuvant Temozolomide for 
Treatment of Newly Diagnosed High-Grade Glioma: A Systematic 
Literature Review 
Lynn S. Ashby 
Barrow Neurological Institute, lashby@chw.edu 
Kris A. Smith 
Barrow Neurological Institute, kris.smith@bnineuro.net 
Baldassarre Stea 
Follow this and additional works at: https://scholar.barrowneuro.org/neurology 
Recommended Citation 
Ashby, Lynn S.; Smith, Kris A.; and Stea, Baldassarre, "Gliadel Wafer Implantation Combined With Standard 
Radiotherapy and Concurrent Followed by Adjuvant Temozolomide for Treatment of Newly Diagnosed 
High-Grade Glioma: A Systematic Literature Review" (2016). Neurology. 23. 
https://scholar.barrowneuro.org/neurology/23 
This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been 
accepted for inclusion in Neurology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. 
For more information, please contact molly.harrington@dignityhealth.org. 
REVIEW Open Access
Gliadel wafer implantation combined with
standard radiotherapy and concurrent
followed by adjuvant temozolomide for
treatment of newly diagnosed high-grade
glioma: a systematic literature review
Lynn S. Ashby1*, Kris A. Smith2 and Baldassarre Stea3
Abstract
Since 2003, only two chemotherapeutic agents, evaluated in phase III trials, have been approved by the US Food
and Drug Administration for treatment of newly diagnosed high-grade glioma (HGG): Gliadel wafers (intracranially
implanted local chemotherapy) and temozolomide (TMZ) (systemic chemotherapy). Neither agent is curative, but
each has been shown to improve median overall survival (OS) compared to radiotherapy (RT) alone. To date, no
phase III trial has tested these agents when used in sequential combination; however, a number of smaller trials
have reported favorable results. We performed a systematic literature review to evaluate the combination of Gliadel
wafers with standard RT (60 Gy) plus concurrent and adjuvant TMZ (RT/TMZ) for newly diagnosed HGG. A literature
search was conducted for the period of January 1995 to September 2015. Data were extracted and categorized,
and means and ranges were determined. A total of 11 publications met criteria, three prospective trials and eight
retrospective studies, representing 411 patients who received Gliadel plus standard RT/TMZ. Patients were similar in
age, gender, and performance status. The weighted mean of median OS was 18.2 months (ten trials, n = 379, range
12.7 to 21.3 months), and the weighted mean of median progression-free survival was 9.7 months (seven trials,
n = 287, range 7 to 12.9 months). The most commonly reported grade 3 and 4 adverse events were myelosuppression
(10.22 %), neurologic deficit (7.8 %), and healing abnormalities (4.3 %). Adverse events reflected the distinct
independent safety profiles of Gliadel wafers and RT/TMZ, with little evidence of enhanced toxicity from their use
in sequential combination. In the 11 identified trials, an increased benefit from sequentially combining Gliadel
wafers with RT/TMZ was strongly suggested. Median OS tended to be improved by 3 to 4 months beyond that
observed for Gliadel wafers or TMZ when used alone in the respective phase III trials. Larger prospective trials of
Gliadel plus RT/TMZ are warranted.
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Background
Gliadel wafers (Arbor Pharmaceuticals, Atlanta, GA) are
biodegradable copolymers (prolifeprospan 20) impreg-
nated with the alkylating agent carmustine (1,3-bis(2-
chloroethyl)-1-nitrosurea (BCNU)). Gliadel wafers were
developed for treatment of high-grade glioma (HGG)
beginning in the 1990s in order to overcome the limita-
tions of blood-brain barrier impermeability to antineo-
plastic agents. Despite aggressive gross total surgical
resection, HGG remains incurable because of the infil-
trative nature of the disease, which progresses diffusely
but commonly recurs locally within 2 cm of the original
tumor bed [1]. Approved by the US Food and Drug Ad-
ministration (FDA) as an active antineoplastic agent ad-
ministered intravenously for treatment of glioblastoma
multiforme (GBM), carmustine was selected as the best
candidate for development of surgically implantable
polymers because of its documented efficacy [2–4].
Initial work by Brem et al. demonstrated the safety
and efficacy of Gliadel wafers for GBM in humans [5–7].
A phase III multicenter, double-blind trial in 222 pa-
tients with recurrent GBM demonstrated increased me-
dian overall survival (OS) with Gliadel wafers compared
with placebo wafers (31 vs 23 weeks, hazard ratio (HR)
0.67, 95 % confidence interval (CI) 0.51–0.90, p = 0.006)
[5]. Subsequently, based on the survival advantage seen
in recurrent GBM, Gliadel wafer implantation was inves-
tigated as potential initial therapy in patients with newly
diagnosed HGG tumors in two phase III multicenter,
double-blind, placebo-controlled trials [8–10]. Both trials
reported a significant increase in median OS for patients
implanted with Gliadel wafers compared to those im-
planted with placebo wafers. In the 32-patient Valtonen
et al.’s trial of surgical resection and implantation of
Gliadel wafers versus placebo, median OS increased
from 39.9 to 58.1 weeks (p = 0.012) [9]. In the 240-
patient Westphal et al.’s trial, median OS increased
from 11.6 to 13.9 months (log-rank p = 0.03, stratified
by country) [8, 10]. The FDA approved Gliadel wafers
for the treatment of recurrent GBM in 1997 and for
the treatment of newly diagnosed HGG (World
Health Organization (WHO) grade III and grade IV
glioma) in 2003.
In 2005, the European Organization for Research and
Treatment of Cancer (EORTC) Brain Tumor and
Radiotherapy Groups and the National Cancer Institute
of Canada (NCIC) published the results of a phase III
multicenter, double-blind, placebo-controlled trial treating
573 patients with radiotherapy (RT) alone versus RT with
concurrent daily oral temozolomide (TMZ) followed by
6 cycles of adjuvant TMZ for five consecutive days every
28 days (a regimen abbreviated here as RT/TMZ) [11, 12].
The EORTC/NCIC study demonstrated significant im-
provements with RT/TMZ compared to RT alone: median
OS increased from 12.1 months (95 % CI 11.2–13.0) to
14.6 months (95 % CI 13.2–16.8), and 2-year OS increased
from 10.9 % (95 % CI 6.8–14.1 %) to 27.2 % (95 % CI
21.2–31.7 %). In 2005, the FDA approved TMZ (Temodar,
Merck & Co., Kenilworth, NJ) for use in newly diagnosed
GBM in accordance with the dose schedule established by
the EORTC/NCIC study. Thereafter, this RT/TMZ regi-
men has been generally adopted as the “standard of care”
for histologically confirmed GBM following surgical resec-
tion at initial diagnosis.
The phase III trials of Gliadel wafers and the EORTC/
NCIC phase III trial of RT/TMZ represented major con-
tributions to the progress of treatment for adults with
HGG [13–15]. Nonetheless, the prognosis for newly di-
agnosed HGG, especially for GBM, continues to be un-
acceptably poor. For the period of 1999 to 2011, as
reported by the Central Brain Tumor Registry of the
USA, 1-year and 2-year survival rates for patients with
GBM were 36.5 and 14.8 %, respectively [16]. More re-
cent large phase III trials of approaches such as dose-
intensification schedules of TMZ, the addition of the
anti-angiogenic agent bevacizumab, or other novel ther-
apies like cilengitide have failed to show improved sur-
vival for GBM beyond what was originally achieved
with RT/TMZ in the EORTC/NCIC trial [17–20]. Like-
wise, the strategy of increasing radiation dose by either
radioactive seed implantation or stereotactic radiosur-
gery failed to achieve meaningful increases in median
OS [21, 22].
With very few FDA-approved treatments available for
patients with newly diagnosed GBM, and with even
fewer available for anaplastic WHO grade III glioma, se-
quential treatment with Gliadel wafers at the time of
surgical resection followed by the RT/TMZ regimen
warrants reasonable consideration. Although neither
agent is curative, Gliadel wafers and TMZ have each
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increased median survival by about 2 months when ad-
ministered with RT compared to RT alone. Further
improvement in survival might result from the combin-
ation of the tumoricidal mechanisms and effects of these
agents used sequentially. Moreover, between surgical re-
section and initiation of cranial radiation, there is a
scheduled delay varying from 3 to 6 weeks—a critical
time gap during which Gliadel wafers provide active an-
tineoplastic treatment when implanted post-resection.
Concerns have been expressed about potential adverse
effects when Gliadel wafers are delivered as part of a
regimen with standard RT/TMZ because sequential ad-
ministration of the therapies has not been evaluated in a
prospective, randomized, phase III trial [23]. However,
as a significant number of small phase I and II trials
have been conducted globally testing this hypothesis, we
felt that it would be worthwhile to analyze this body of
literature in order to derive a clinically meaningful
consensus opinion. In this systematic literature review,
we analyze the relative risks and benefits of the multi-
modal combination of Gliadel wafers plus standard RT/
TMZ for treatment of patients with newly diagnosed
HGG.
Methods
Search methodology
The purpose of this systematic review is to assess and
summarize the complex body of literature on the use of
Gliadel plus standard RT/TMZ in the treatment of
newly diagnosed HGG, resolving conflicting reports and
evaluating the consistency of results in these trials.
A literature search of PubMed and EMBASE was con-
ducted in September 2015 to identify prospective and
retrospective clinical trials of Gliadel plus standard RT/
TMZ (Fig. 1). The inclusive search dates were from
January 1995 through September 2015. Specific search
Fig. 1 Flow diagram of the literature search for trials about Gliadel wafers combined with standard radiotherapy and concurrent followed by
adjuvant temozolomide for the treatment of high-grade glioma structured in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISM) schema [26]
Ashby et al. World Journal of Surgical Oncology  (2016) 14:225 Page 3 of 15
terms included Gliadel, carmustine, BCNU, wafers, and
TMZ. The search results were filtered and restricted to
clinical trials in humans with abstracts and full manu-
scripts, excluding reports that were limited to confer-
ence or congress abstracts.
After the searches were completed, the abstract of
each identified publication was reviewed to determine
relevance. All studies in which Gliadel wafers were im-
planted at the time of surgical resection and followed by
RT/TMZ were obtained, and their reference lists were
reviewed. Excluded from analysis were review articles,
editorials, and clinical trials of therapies other than the
multimodal combination therapy under investigation. In-
dividual case reports of Gliadel plus standard RT/TMZ
were also excluded. We eliminated any duplicate subject
cohorts reported in more than one publication.
Data extraction
The efficacy variables assessed were those related to sur-
vival: median OS in months, 1- and 2-year OS rates, me-
dian progression-free survival (PFS) in months, and 6-
month and 1-year PFS rates.
Data on grade 3 and 4 adverse events were also ex-
tracted and reviewed. In the Common Terminology Cri-
teria for Adverse Events (CTCAE), version 4.0, a grade 3
adverse event is defined as “severe or medically signifi-
cant but not immediately life-threatening; hospitalization
or prolongation of hospitalization indicated; disabling;
limited self-care activities of daily living.” A grade 4 ad-
verse event is one that has “life-threatening conse-
quences, where urgent intervention is needed” [24]. The
adverse events reported in the 11 trials included in this
analysis were organized into 12 different categories: (1)
cerebral edema; (2) healing abnormalities (including
cerebral spinal fluid (CSF) leak and hydrocephalus); (3)
intracranial hypertension; (4) intracranial infection (in-
cluding abscess, cerebritis, hydrocephitis, and meningi-
tis); (5) neurological deficit (including aphasia, change of
mental status, epilepsy, and hemiparesis); (6) seizures;
(7) elevated liver enzymes; (8) fatigue; (9) gastrointestinal
disorders (including nausea, vomiting, and constipation);
(10) myelosuppression (including anemia, lymphopenia,
leukocytopenia, and thrombocytopenia); (11) skin and
subcutaneous disorders; and (12) thromboembolic
events (including deep vein thrombosis (DVT) and pul-
monary embolism).
For comparison purposes, these adverse event data
points were also extracted from the publication of
the EORTC/NCIC phase III study of RT/TMZ, as
well as from the two pivotal phase III clinical trials
of Gliadel wafers for treatment of newly diagnosed
HGG, as reported in the US product label for Gliadel
wafers [8–12, 25].
Results
Search results
The PubMed and EMBASE literature searches yielded a
combined pool of 154 possible references. Duplicates be-
tween the databases were eliminated; conference or con-
gress abstracts were eliminated; and case reports or
articles not related to the treatment of HGG were elimi-
nated. Thirty-eight articles remained (including review
articles), and these were obtained and analyzed specific-
ally for prospective or retrospective clinical trials in
which Gliadel wafers were combined with RT/TMZ for
treatment of HGG. A total of 11 articles were found that
reported efficacy and safety results for Gliadel plus
standard RT/TMZ, without duplication of subject co-
horts. A flow diagram of the literature search strategy
and results, structured in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses schema, appears in Fig. 1 [26].
Study characteristics
Summarized in Table 1 are the 11 trials selected for in-
clusion in this analysis. The 11 reports were published
between 2009 and 2015 by investigators from France (n
= 5), Japan (n = 1), Germany (n = 1), Italy (n = 1), and the
USA (n = 3) [27–37]. Five of the trials were conducted at
multiple sites. Three were prospective clinical trials of
Gliadel plus standard RT/TMZ, including one phase I/II
study from Japan (which also included patients with re-
current HGG) and one phase II study from the USA.
Eight were retrospective clinical trials.
Two of the retrospective studies compared Gliadel
plus standard RT/TMZ with other treatment arms. In a
single-center retrospective study, McGirt et al. compared
Gliadel plus RT/TMZ (n = 33) to treatment with Gliadel
wafers alone (n = 78) and to a third group treated with
standard RT/TMZ alone (n = 45) [31]. In another single-
center retrospective study, Noel et al. compared Gliadel
plus standard RT/TMZ (n = 28) with standard RT/TMZ
alone (n = 45) [34].
In one of the 11 trials, begun before the EORTC/NCIC
results had been published, the dose schedule of RT/TMZ
differed from the standard schedule followed in the other
trials. Burri et al. included an immediate postoperative 5-
day cycle of TMZ beginning on day 4 ± 1, dosed at 150–
200 mg/m2 per day [29]. Concurrent TMZ at 75 mg/m2
then began at day 33 ± 1 with RT; after completion of con-
current treatment, adjuvant TMZ was begun and adminis-
tered at 150–200 mg/m2 per day for 5 days per 28-day
cycle for up to 10 cycles or until progression or patient in-
tolerance [29]. Because the Burri et al. trial was a multisite
phase II study, it was included in the analysis. Noel et al.
also similarly employed 1 cycle of pre-RT TMZ in 13 of
the 65 patients enrolled in their trial (including 7 of the 28
patients in the trial who were implanted with Gliadel
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wafers), using a dose of 150 mg/m2 per day for five con-
secutive days before RT began [34].
Altogether, in the 11 trials that met search criteria,
662 patients were treated, of whom 411 (62.1 %) with
newly diagnosed HGG received Gliadel wafers followed
by RT/TMZ.
Patient characteristics
The patients analyzed in these 11 trials were relatively
similar (Table 2). The majority (approximately 85 %) of
these patients had newly diagnosed GBM. The mean age
was 57.9 years (range 17 to 82 years), and 60.2 % of the
patients were male. The presurgery performance status,
measured by the Karnofsky Performance Status (KPS)
scale, was ≥80 for the majority of patients. In one of the
trials, the Eastern Cooperative Oncology Group (ECOG)
scale was used to assess cognitive performance status;
75 % of the patients were scored either PS 0 (normal ac-
tivity) or PS 1 (some symptoms) [33].
In the majority of these trials, the percentage of pa-
tients who underwent complete resection was near to or
greater than 80 %. In three trials, however, all performed
by French investigators, rates of complete resection were
lower. Of the 22 patients in the study by Miglierini et al.,
only 50 % had complete resection [33]. Of the 38
patients in the combination-therapy arm and the 37
patients in the RT/TMZ-only arm in the study by
Noel et al., only 35.7 and 24.3 %, respectively, had
complete resection [34]. Of the total 83 patients in the
study by Pavlov et al., 49.1 % had complete resection; 61
(73.5 %) of the 83 patients received Gliadel plus standard
RT/TMZ [36].
In the study by Noel et al., which compared Gliadel
plus RT/TMZ to RT/TMZ alone, there were significantly
Table 1 Study characteristics reported in 11 trials of Gliadel wafers combined with standard radiotherapy and concurrent followed
by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma
Clinical trial Yr Country Sites Study type
Treatment years
Treatments/arms ND HGG (n) Gliadel wafer
plus RT/TMZ (n)
GBM (n) Other
HGG (n)
Aoki et al. [27] 2014 Japan 10 Phase I/II study
2009 to 2012
Resection + Gliadel
wafer + RT/TMZ
16 16 9 7
Bock et al. [28] 2010 Germany 7 Retrospective analysis for
safety risks
2005 to 2008
Resection + Gliadel
wafer + RT/TMZ
44 44 44 0
Burri et al. [29] 2015 USA 4 Phase II/2003 to 2008 Resection + Gliadel
wafer + early TMZ
(day 4) + RT/TMZ
46 46 43 3
Duntze et al. [30] 2012 France 17 Prospective, observational
2007 to 2009
Resection + Gliadel
wafer + RT/TMZ
92 65 74 18
McGirt et al. [31] 2009 USA 1 Retrospective analysis
1997 to 2006
(1) Resection +
Gliadel wafer + RT/TMZ
33 33 33 0
(2) Resection +
Gliadel wafer + RT
78 78 0
(3) Resection/biopsy
+ RT/TMZ
45 45 0
Menei et al. [32] 2010 France 26 Retrospective analysis
2005 to 2006
(1) Resection +
Gliadel wafer + RT/TMZ
43 43 72 11
(2) Resection + Gliadel
wafer + other regimens
40
Miglierini et al. [33] 2012 France 1 Retrospective analysis
2006 to 2010
Resection + Gliadel
wafer + RT/TMZ
24 22 16 8
Noel et al. [34] 2012 France 1 Retrospective analysis
2007 to 2008
(1) Resection +
Gliadel wafer + RT/TMZ
28 28 20 8
(2) Resection/biopsy
+ RT/TMZ
37 16 21
Pan et al. [35] 2008 USA 1 Retrospective analysis
2003 to 2005
Resection + Gliadel
wafer + RT/TMZ
21 21 21 0
Pavlov et al. [36] 2015 France 1 Retrospective analysis
2004 to 2012
Resection + Gliadel
wafer + RT/TMZ
83 61 83 0
Salvati et al. [37] 2011 Rome 1 Retrospective analysis
2006 to 2008
Resection + Gliadel
wafer + RT/TMZ
32 32 NA NA
GBM glioblastoma multiforme, HGG high-grade glioma, ND HGG newly diagnosed high-grade glioma, RT/TMZ radiotherapy + temozolomide regimen, Yr year
published, NA not available
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fewer patients with grade III HGG in the combination-
therapy arm (n = 8) than in the RT/TMZ-only arm (n =
21) (p = 0.04) [34]. The investigators acknowledged that
this imbalance could mask the benefit of Gliadel wafers
used with RT/TMZ because of the better survival profile
of grade III HGG patients compared to those with GBM.
Methylation of the promoter region of the methyl
guanine methyl transferase (MGMT) gene has been
demonstrated to be both a strong prognostic marker for
outcome and a predictive marker for response to alkylat-
ing agents [38, 39]. Only two of the trials in this system-
atic review reported MGMT analysis. Burri et al.
reported MGMT promoter methylation status for 22 of
43 patients with GBM (out of 46 patients total in the
study) [29]. In the study by Noel et al., MGMT promoter
methylation status was reported for all 65 patients: 24
patients were methylated, 27 patients were unmethy-
lated, and 14 patients were not analyzed [34].
In these 11 clinical trial reports, there were few de-
scriptive comments regarding procedural details for the
surgical implantation of Gliadel wafers. Overall, patients
received an average of eight Gliadel wafers, with a mi-
nority receiving fewer than five wafers. In the studies by
Duntze and Menei, the range of Gliadel wafers im-
planted was reported to be from 1 to 9 [30, 32]. Duntze
et al. reported no correlation between preoperative
tumor volume and the number of implanted Gliadel
wafers [30]. However, Pavlov et al. found a significant
positive correlation between preoperative tumor vol-
ume and the number of implanted wafers (p < 0.001),
with the number of implanted wafers increasing with
tumor volume [36].
Table 2 Demographics and procedure characteristics reported in 11 trials of Gliadel wafers combined with standard radiotherapy
and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma
Clinical trial Treatments/arms ND HGG
(n)
Gliadel wafer
plus RT/TMZ (n)
Mean age
(range)
% male KPS
score
EOR MGMT status # Gliadel
wafers
Aoki et al. [27] Resection + Gliadel
wafer + RT/TMZ
16 16 50 (21–63) 50.0 % 87.5 % >80 Mean 91.9 % No ≤8
Bock et al. [28] Resection + Gliadel
wafer + RT/TMZ
44 44 57 (28–74) 63.6 % 81 ± 15.3 86 % total No 7.3 ± 1.3
Burri et al. [29] Resection + Gliadel
wafer + early TMZ
(day 4) + RT/TMZ
46 46 56 (19–73) 60.9 % 80 70 % total Yes, performed
on 22 pts
8
Duntze et al. [30] Resection + Gliadel
wafer + RT/TMZ
92 65 58 (34–76) 69.6 % Median 80 86 % >90 % No 6.5
McGirt et al. [31] (1) Resection + Gliadel
wafer + RT/TMZ
33 33 57 (50–81) 60.0 % 80 77 % total No 8
(2) Resection + Gliadel
wafer + RT
78 NA NA
(3) Resection/biopsy +
RT/TMZ
45 (18–70) NA
Menei et al. [32] (1) Resection + Gliadel
wafer + RT/TMZ
43 43 60 (18–80) 58.1 % Median 80 84.3 % >90 % No 8
(2) Resection + Gliadel
wafer + other regimens
40
Miglierini et al. [33] Resection + Gliadel
wafer + RT/TMZ
24 22 Mean 60.25
Median 63
5 pts >70
70.8 % 75 % PS
0–1
50 % total No 8
Noel et al. [34] (1) Resection + Gliadel
wafer + RT/TMZ
28 28 61 (17–82) 53.6 % 92.8 % ≥80 35.7 % total Yes 8
(2) Resection/biopsy +
RT/TMZ
37 61 (17–82) 40.5 % 81.1 % ≥80 24.3 % total
Pan et al. [35] Resection + Gliadel
wafer + RT/TMZ
21 21 60 (48–83) 66.7 % Median 80 67 % total No 8
Pavlov et al. [36] Resection + Gliadel
wafer + RT/TMZ
83 61 59.9 (21–78) 60.2 % 94 % ≥70 49.1 % total No 7.1 (3–13)
Salvati et al. [37] Resection + Gliadel
wafer + RT/TMZ
32 32 Median 58.5
(35–72)
50.0 % Mean 80.6 100 % total No 8 (5–10)
EOR extent of resection, KPS Karnofsky Performance Status, ND HGG newly diagnosed high-grade glioma, MGMT O6-methylguanine-DNA methyltransferase methy-
lation, RT/TMZ radiotherapy + temozolomide regimen, NA not available
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Efficacy results
Median overall survival
Efficacy data from these trials are presented in Table 3.
The weighted mean of median OS was 18.2 months (ten
trials, n = 379), with a range from 12.7 months (n = 44)
to 21.3 months (n = 33) (Fig. 2). In the study by Mcgirt
et al., median OS was longer for Gliadel plus RT/TMZ
than for Gliadel wafers alone (21.3 vs 12.4 months, p =
0.005) or for RT/TMZ alone (21.3 vs 14.7 months, p <
0.001) [31]. In the study by Noel et al., median OS was
not significantly different for Gliadel plus RT/TMZ com-
pared to RT/TMZ alone (20.6 vs 20.8 months) [34].
However, this outcome for the overall study cannot be
considered conclusive, because for the subset of patients
with WHO grade III HGG (n = 29), the median OS had
not been reached at the time of data analysis. For the
subset of patients with GBM (n = 36), the median OS
was reached and was demonstrably longer for Gliadel
plus RT/TMZ than for RT/TMZ alone (20.8 vs
13.8 months).
Overall 1- and 2-year survival rates
The weighted mean of 1-year OS rates in these trials
was 76.34 % (seven trials, n = 253), with a range of
58.0 % (n = 44) to 100 % (n = 16; n = 32); and the
weighted mean of 2-year OS rates was 33.73 % (eight tri-
als, n = 275), with a range of 13.0 % (n = 44) to 68.8 % (n
= 16) (Fig. 3). In the study by Noel et al., there was no
Table 3 Efficacy data reported in 11 trials of Gliadel wafers combined with standard radiotherapy and concurrent followed by
adjuvant temozolomide for treatment of newly diagnosed high-grade glioma
Clinical trial Treatments/arms ND HGG
(n)
Gliadel wafer
plus RT/TMZ (n)
Median OS
(months)
OS, 1 year
(%)
OS, 2 years
(%)
Median PFS
(months)
PFS, 6
months (%)
PFS, 1 year
(%)
Aoki et al. [27] Resection + Gliadel
wafer + RT/TMZ
16 16 20.2a 100.0 % 68.8 %,
44.4%a
NA 75.0 % 62.5 %
Bock et al. [28] Resection + Gliadel
wafer + RT/TMZ
44 44 12.7 58.0 % 13.0 % 7 63.0 % 35.0 %
Burri et al. [29] Resection + Gliadel
wafer + early TMZ
(day 4) + RT/TMZ
46 46 18 76.0 % 33.0 % 8.5 72.0 % 33.0 %
Duntze et al. [30] Resection + Gliadel
wafer + RT/TMZ
92 65 18.8 70.0 % 37.0 % 10.5 74 % 41.0 %
McGirt et al. [31] (1) Resection + Gliadel
wafer + RT/TMZ
33 33 21.3 NA 36.0 % NA 93.0 % NA
(2) Resection + Gliadel
wafer + RT
78 12.4b NA NA NA NA NA
(3) Resection/biopsy +
RT/TMZ
45 14.7c NA NA NA NA NA
Menei et al. [32] (1) Resection + Gliadel
wafer + RT/TMZ
43 43 17 NA NA NA NA NA
(2) Resection + Gliadel
wafer + other regimens
40 NA NA NA NA NA NA
Miglierini et al.
[33]
Resection + Gliadel
wafer + RT/TMZ
24 22 19.2 78.0 % 24.0 % 12.3 81.50 % 52.0 %
Noel et al. [34] (1) Resection + Gliadel
wafer + RT/TMZ
28 28 20.6 78.6 % 40.9 % 12.9 NA 52.0 %
(2) Resection/biopsy +
RT/TMZ
37 20.8 78.4%d 33.3 % 14 NA 55.0%e
Pan et al. [35] Resection + Gliadel
wafer + RT/TMZ
21 21 17 NA 39.0 % 8.5 71.0 % NA
Pavlov et al. [36] Resection + Gliadel
wafer + RT/TMZ
83 61 19.5 NA NA 8.5 NA NA
Salvati et al. [37] Resection + Gliadel
wafer + RT/TMZ
32 32 NA 100 % NA NA 100 % NA
EOR extent of resection, ND HGG newly diagnosed high-grade glioma, OS overall survival, PFS progression-free survival, RT/TMZ radiotherapy + temozolomide regi-
men, NA not available
aGlioblastoma patients only
bGliadel plus RT/TMZ versus Gliadel wafer alone, p = 0.005
cGliadel plus RT/TMZ versus RT/TMZ, p < 0.001
dGliadel plus RT/TMZ versus RT/TMZ, log-rank test for overall survival, p = 0.81
eGliadel plus RT/TMZ versus RT/TMZ, log-rank test for progression-free survival, p = 0.89
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significant difference in 1-year survival rates between
Gliadel plus RT/TMZ and RT/TMZ alone (78.6 vs
78.44 %, respectively, log-rank p = 0.89) [34]. For the
subset of patients with GBM, the differences in 1-year
and 2-year survival rates between Gliadel plus RT/TMZ
therapy and RT/TMZ alone were 75.0 versus 62.5 %,
and 38.9 versus 0 %, respectively, approaching statistical
significance (log-rank p = 0.067).
Progression-free survival
The weighted mean of median PFS in these trials was
9.7 months (seven trials, n = 287), with a range from
7 months (n = 44) to 12.9 months (n = 28) (Fig. 4). The
weighted mean for PFS was 78.7 % at 6 months (eight
trials, n = 279) and 45.9 % at 12 months (six trials, n =
221). PFS ranged from 63.0 % (n = 44) to 100 % (n = 32)
at 6 months and from 33.0 % (n = 46) to 62.5 % (n = 16)
at 12 months. In the study by Noel et al., median PFS
was lower for Gliadel plus RT/TMZ than for RT/TMZ
alone (12.9 vs 14 months), and the PFS rate at 12 months
(no 6-month rates were provided) for Gliadel plus RT/
TMZ was also less than that for RT/TMZ alone (52.0 vs
55.0 %), but these rates were not significantly different
(log-rank p = 0.89) [34]. In contrast, for the subset of pa-
tients in the Noel et al.’s trial with GBM, the median
PFS was greater for Gliadel plus RT/TMZ than for RT/
TMZ alone (9.7 vs 7.8 months), as were the PFS rates at
6 and 12 months (6 months, 73.7 vs 64.6 %; 12 months,
36.8 vs 32.3 %); however, these PFS rates were again not
significantly different (log-rank p = 0.4).
Subgroup analyses and prognostic factors
In patients treated with Gliadel plus RT/TMZ, Duntze
et al. found no statistically significant difference in OS
associated with tumor grade, KPS score ≥70, or age [30].
However, these investigators did find a difference ap-
proaching statistical significance for PFS between pa-
tients with <90 % resection and patients with ≥90 %
resection (p = 0.057).
By multivariate analysis, Noel et al. found that
unmethylated MGMT was a negative prognostic factor
for PFS (p = 0.017, HR 2.8, 95 % CI 1.2–7) and that the
combination of unmethylated MGMT and a radiation
dose <60 Gy was a negative prognostic factor for OS (p
= 0.02, HR 6.3, 95 % CI 2–20) [34]. In the Burri et al.
clinical trial, patients with unmethylated MGMT (n =
19) experienced shorter median OS but longer median
PFS than patients with methylated MGMT (n = 14) (18.2
vs 27.3 months for median OS; 8.9 vs 7.4 months for
median PFS) [29].
By multivariate analysis, Pavlov et al. found that tumor
volume ≥40 cm3 (HR 3.62, 95 % CI 1.53–9.05, p =
0.003), subtotal or total resection (HR 0.45, 95 % CI
0.21–0.99, p = 0.005), and ≥8 Gliadel wafers (HR 0.32,
Fig. 2 Median overall survival (OS) in months as reported in trials of Gliadel wafers combined with standard radiotherapy (RT) and concurrent
followed by adjuvant temozolomide (TMZ) for the treatment of high-grade glioma. The median OS values of these trials are compared with the
values for the active treatment arm of the 240-patient phase III clinical trial of Gliadel wafers plus RT [8, 10] (column 1) and the active treatment
arm of the phase III clinical trial of RT/TMZ (column 2) [11, 12]
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Fig. 4 Median progression-free survival (PFS) in months as reported in trials of Gliadel wafers combined with standard radiotherapy (RT) and
concurrent followed by adjuvant temozolomide (TMZ) for the treatment of high-grade glioma. The median PFS values of these trials are
compared with the values for the active treatment arm of the 240-patient phase III clinical trial of Gliadel wafers plus RT [8, 10] (column 1) and
the active treatment arm of the phase III clinical trial of RT/TMZ (column 2) [11, 12]
Fig. 3 Overall survival (OS) at 1 year and 2 years as reported in trials of Gliadel wafers combined with standard radiotherapy (RT) and concurrent
followed by adjuvant temozolomide (TMZ) for the treatment of high-grade glioma. The 1-year and 2-year OS values of these trials are compared
with the values for the active treatment arm of the 240-patient phase III clinical trial of Gliadel wafers plus RT [8, 10] (column 1) and the active
treatment arm of the phase III clinical trial of RT/TMZ (column 2) [11, 12]
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95 % CI 0.14–0.74, p = 0.008) were positive prognostic
factors for OS in patients who received Gliadel plus RT/
TMZ (n = 61) [36]. Patients implanted with ≥8 Gliadel
wafers survived significantly longer than patients im-
planted with <8 Gliadel wafers (median OS 24.5 vs
13 months, p = 0.021). Patients who had ≥6 cycles of ad-
juvant TMZ survived significantly longer than patients
who had <6 cycles of adjuvant TMZ (27 vs 16 months,
p < 0.001).
Safety results
Grade 3 and 4 adverse events were reported in nine of
the 11 trials and are categorized and listed in Table 4.
The trials by McGirt and Menei did not specifically des-
ignate the severity of adverse events using CTCAE
adverse-event grades [31, 32]. Also, two of the trials did
not break out adverse events for the subgroup of pa-
tients with newly diagnosed HGG who specifically re-
ceived Gliadel plus RT/TMZ. Aoki et al. merged adverse
events for 16 patients receiving Gliadel plus RT/TMZ
for newly diagnosed HGG with those for eight patients
receiving Gliadel wafers for recurrent GBM [27]. Duntze
et al. reported merged adverse events for all 92 patients
with newly diagnosed HGG who received Gliadel
wafers—a population that included but was not limited
to the 65 patients in that study who specifically received
Gliadel wafers plus RT/TMZ [30].
In the nine trials that reported grade 3 and 4
adverse events, 147 grade 3 and 4 adverse events
were registered for 372 patients. The most commonly
reported grade 3 and 4 adverse events were
myelosuppression (10.22 %, n = 38), neurological def-
icit (7.8 %, n = 29), healing abnormalities (4.3 %, n =
16), and seizures (3.0 %, n = 11).
Two of the trials reported a considerable majority of
the grade 3 and 4 adverse events. In the retrospective
analysis by Bock et al., 19 patients (43 %) experienced
46 grade 3 and 4 adverse events [28]. These investiga-
tors found a higher incidence of intracranial infections
and CSF leaks than in the original phase III clinical tri-
als of Gliadel wafers, some of these adverse events oc-
curring after discharge. However, Bock et al. noted that
after introducing a risk-management strategy to address
patient selection, surgical techniques, and follow-up
schedules, the incidence of implantation-site-related
complications dropped significantly [40]. In the phase
II clinical trial by Burri et al., in which 39 adverse
events were reported, adjuvant TMZ was administered
at a dose of 150–200 mg/m2 [29]. The investigators re-
ported that nine of the patients receiving 200 mg/m2 of
TMZ experienced one or more episodes of grade 3 or 4
thrombocytopenia after the initial pre-radiotherapy
cycle of adjuvant TMZ.
Except for the one trial reported by Bock et al.
[28], none of the others found that combining Glia-
del plus RT/TMZ caused more myelosuppression or
other adverse events than either Gliadel wafers alone
or RT/TMZ alone [31]. As expressly noted by
Duntze et al. regarding the results of their prospect-
ive clinical trial, there was no apparent enhancement
of toxicity due to the combination of Gliadel plus
RT/TMZ [30].
Table 4 Grade 3 and 4 adverse events reported in nine trials of Gliadel wafers combined with standard radiotherapy and concurrent
followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma
Clinical trial Number CE HA IH II ND S LE F GI MY SK TE Total, n
Aoki et al. [27]a 24 2 5 1 2 1 4 15
Bock et al. [28] 44 7 11 6 8 7 1 6 46
Burri et al. [29] 46 1 2 7 3 3 3 18 2 39
Duntze et al. [30]b 92 3 2 5 12 7 29
Miglierini et al. [33] 24 3 3 6
Noel et al. [34] 28 4 4
Pan et al. [35] 21 1 1 2
Pavlov et al. [36] 61 2 3 1 6
Salvati et al. [37] 32 2 0
Total, n 372 10 16 11 18 29 11 5 1 1 38 1 8 147
Total, % 2.7 % 4.3 % 3.0 % 4.8 % 7.8 % 3.0 % 1.3 % 0.3 % 0.3 % 10.2 % 0.2 % 2.15 % 39.5 %
CE cerebral edema, HA healing abnormalities (including CSF leak and hydrocephalus), IH intracranial hypertension, II intracranial infections (including abscess,
cerebritis, hydrocephitis, and meningitis), ND neurological deficit (including aphasia, change of mental status, epilepsy, and hemiparesis), S seizures, LE elevated
liver enzymes, F fatigue (including fever), GI gastrointestinal disorders (including nausea, vomiting, and constipation), MY myelosuppression (including anemia,
lymphopenia, leukocytopenia, neutropenia, and thrombocytopenia), SK skin and subcutaneous disorders, TE thromboembolic events (including deep vein
thrombosis and pulmonary embolism)
aIncludes 16 patients treated for newly diagnosed high-grade glioma and 8 patients treated for recurrent high-grade glioma
bIncludes all 92 patients treated with Gliadel wafers, of whom 65 received Gliadel plus RT/TMZ
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Discussion
Efficacy of Gliadel plus RT/TMZ
This systematic literature review identified 11 clinical
trials in which Gliadel wafers were used in combination
with RT/TMZ. Of these, eight were retrospective and
three were prospective clinical trials. Altogether, in these
trials, 411 patients with newly diagnosed HGG received
Gliadel plus RT/TMZ.
Systematic review of the efficacy data of these 11 trials
strongly suggests that a therapeutic benefit is achieved
when combining Gliadel wafers and RT/TMZ. The
weighted mean of median OS was 18.2 months (ten tri-
als, n = 379, range 12.7 to 21.3 months), and the
weighted mean of PFS was 9.7 months (seven trials, n =
287, range 7 to 12.9 months). These outcomes are better
than those seen in the treatment arms of the original
phase III clinical trials in which Gliadel wafers or TMZ
were used alone with RT. In the 240-patient phase III
clinical trial of Gliadel wafers, in which patients were
randomized to undergo surgical resection with active or
placebo wafer placement, followed by RT, median OS
was improved from 11.6 to 13.9 months [8]. In both
arms of that trial, median PFS was 5.9 months based on
radiographic and clinical criteria. In the 573-patient
EORTC/NCIC phase III study of RT/TMZ, in which pa-
tients were randomized to RT alone or RT with con-
comitant TMZ followed by 6 cycles of adjuvant TMZ,
median OS was improved from 12.1 to 14.6 months, and
median PFS was improved from 5.0 to 6.9 months [11].
The difference in median OS between the 11 trials ana-
lyzed in the current review and the treatment arm of the
EORTC/NCIC RT/TMZ trial (18.2 vs 14.6 months, a dif-
ference of 3.6 months) exceeds the difference in median
OS between the RT/TMZ and RT-alone arms in the
EORTC/NCIC clinical trial (14.6 vs 12.1 months, a dif-
ference of 2.5 months).
Pallud et al. retrospectively conducted multivariate
and case-matched analyses (controlled propensity-
matched cohorts) comparing outcomes for patients who
received Gliadel plus RT/TMZ (n = 354) versus patients
who received RT/TMZ alone (n = 433) [41]. The French
multicenter cohort that comprised their analysis incor-
porated patients from several of the trials of Gliadel plus
RT/TMZ included in the current systematic review [30,
36]. Median OS and PFS were 20.4 months (95 % CI
19.0–22.7) and 12.0 months (95 % CI 10.7–12.6) for
Gliadel plus RT/TMZ versus 18.0 months (95 % CI
17.0–19.0) and 10.0 months (95 % CI 9.0–10.0) for RT/
TMZ alone (p = 0.0048). For Gliadel plus RT/TMZ ver-
sus RT/TMZ alone, 1-year OS rates were 80.8 % (95 %
CI 76.3–84.6) versus 71.3 % (95 % CI 67.0–75.2), and 2-
year OS rates were 41.0 % (95 % CI 35.2–47.2) versus
30.4 % (95 % CI 26.2–34.9). The combination of Gliadel
plus standard RT/TMZ was independently associated
with longer PFS in patients with subtotal/total surgical
resection in the whole series (adjusted HR 0.76, 95 % CI
0.63–0.92, p = 0.005) and after propensity matching (HR
0.74, 95 % CI 0.60–0.92, p = 0.008). No survival benefit
was found for Gliadel plus RT/TMZ for partial resec-
tion. Gliadel plus RT/TMZ was not independently asso-
ciated with longer OS in the whole series analysis (HR
0.95, 95 % CI 0.80–1.13, p = 0.561) or after propensity
matching (HR 1.06, 95 % CI 0.87–1.29, p = 0.561). The
investigators observed that one explanation for the find-
ing that Gliadel plus RT/TMZ was not an independent
predictor of OS was the use of salvage therapies after
progression—including salvage implantation of Gliadel
wafers in 20.1 % of patients who had received RT/TMZ
alone but in only 4.3 % of patients who had already re-
ceived Gliadel wafers.
The positive findings of our systematic literature re-
view, suggesting additional months of survival with Glia-
del plus RT/TMZ, could constitute an artifact of
temporal bias, reflecting improved surgical procedures
and more aggressive current neuro-oncologic care com-
pared with the experience of historical controls and/or
patient selection bias. On the other hand, the increased
survival benefit could be easily explained by the antineo-
plastic effect of the Gliadel wafers while awaiting the
start of RT/TMZ.
TMZ has demonstrated the ability to deplete the
MGMT repair protein levels in tumor cells [38], result-
ing in improved efficacy of alkylating agents, which may
contribute to the therapeutic synergy seen when com-
bining this agent with Gliadel. Lechapt-Zalcman et al.
retrospectively analyzed 111 tumors from the patients in
the prospective trial conducted by Duntze et al. to deter-
mine the prognostic impact of MGMT on those treated
with Gliadel plus RT/TMZ [42]. In the whole patient
group, median OS was 17.5 months and median PFS
was 10.3 months. Patients with methylated MGMT had
significantly longer median OS than patients with
unmethylated MGMT (21.7 vs 15.1 months, p = 0.025).
Smith et al. reported a positive correlation of MGMT
promoter methylation with survival in a prospective trial
of 30 newly diagnosed GBM patients treated with Glia-
del wafers and Gamma Knife radiosurgical boost
followed by standard fractionated RT (60 Gy over
6 weeks) (but without TMZ, for the EORTC/NCIC data
had not yet been published) [43]. Among the 11 trials
identified for the current analysis, only two undertook
MGMT testing, and none assessed any other relevant
biomarkers.
Safety review
Combination therapy regimens expose patients not only
to the adverse events associated with individual treat-
ments but also to the additive and potentially synergistic
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adverse effects that might derive from the combination
of treatments. In the nine trials that reported grade 3
and 4 adverse events, representing 372 patients who re-
ceived Gliadel plus RT/TMZ, there were 147 grade 3
and 4 adverse events—the most common being myelo-
suppression, neurologic deficit, healing abnormalities,
and seizures. No increased incidence of radiation necro-
sis has been reported in this patient population, despite
the use of RT following the implantation of Gliadel wa-
fers. This is possibly due to the delay of 3 to 4 weeks
that naturally occurs before the start of contemporary
RT. Another possible explanation for the lack of increase
in local toxicity associated with the combination of
Gliadel and RT is that radiation necrosis usually occurs
many months post-RT, peaking at approximately
18 months in a population of patients with a constant
attrition due to progression of their disease.
To date, no large prospective controlled trial has docu-
mented the adverse-event profile of the combination of
Gliadel wafers with RT/TMZ. However, the adverse
events associated with the individual components of this
multimodal regimen have been prospectively studied: for
Gliadel wafers with postoperative external beam RT
(60 Gy) in the phase III trials reported by Valtonen et al.
[9] and Westphal et al. [8, 10] and for TMZ used con-
currently with and then following 60-Gy involved field
cranial radiation in the EORTC/NCIC phase III trial re-
ported by Stupp et al. [11]. The adverse events in these
phase III trials are listed in Table 5.
In the nine trials reporting grade 3 and 4 adverse
events, these events seemed to reflect the distinct and
independent adverse-event profiles of Gliadel wafers and
RT/TMZ, considered separately. Specifically, there was
little evidence of any enhanced toxicity from combin-
ation therapy. Carmustine, when released from the poly-
meric wafers into local tissue after implantation, results
in only trace amounts of drug in the systemic circula-
tion. This suggests that adverse events such as fatigue,
gastrointestinal disorders, and myelosuppression are
likely due to the systemic toxicity of RT/TMZ without
influence from the local effects of the Gliadel wafer im-
plant [44].
In the phase III clinical trials of Gliadel wafers, adverse
events were not graded, but there was an explicit com-
parison between the active and placebo treatment arms
(Table 5) [8, 10, 25]. Neurological adverse events in the
treatment arms—seizures, neurological deficits, and op-
erative complications—were similar. Further, postopera-
tive complications were similar, except for (1) healing
abnormalities commonly related to CSF leaks (16.0 % for
the active treatment arm vs 12.0 % for placebo) and (2)
intracranial hypertension (9.0 vs 2.0 %). Since the FDA
approval of Gliadel wafers for newly diagnosed HGG in
2003, risk-management articles have recommended
“best-practice” surgical techniques for reducing adverse
events associated with Gliadel wafer implantation [40,
45]. In this regard, ensuring a watertight dural seal is
mandatory for reducing any risk of CSF leak.
That the adverse-event profile of Gliadel wafers can be
safely managed with good technique is evidenced by
reports from the Johns Hopkins University School of
Medicine, where the Gliadel wafer technology was
Table 5 Adverse events associated with Gliadel wafers combined with standard radiotherapy (RT) and concurrent followed by
adjuvant temozolomide (TMZ) compared with adverse events in (1) the phase III RT/TMZ clinical trial, (2) the phase III Gliadel clinical
trials, and (3) the Attenello et al.’s retrospective comparison of patients who underwent craniotomy with and without Gliadel wafer
implantation
Clinical trial Number CE HA IH II ND S LE F GI MY SK TE UI
Grade 3 and 4 AEs, 9
Gliadel wafers + RT/TMZ, %
372 2.7 % 4.3 % 3.0 % 4.8 % 7.8 % 3.0 % 1.3 % 0.3 % 0.3 % 10.2 % 0.2 % 2.15 %
Grade 3 and 4 AEs, Phase III
RT/TMZ trial, [11, 12] RT/
TMZ treatment arm, %
287 7.0 % 13.0 % 2.0 % 16.0 % 3.0 % 6.0 %
AEs, Gliadel phase III clinical
trials, Gliadel wafer arm, %
[8–10, 25]
120 23.0 % 16.0 % 9.0 % 5.0 % 16.0 % 33.0 % 27.0 % 700 % 18.0 %
AEs, Gliadel phase III clinical
trials, placebo wafer arm, %
[8–10, 25]
120 19.0 % 12.0 % 2.0 % 6.0 % 10.0 % 38.0 % 15.0 % 47.0 % 17.0 %
AEs, Attenello et al., [46]
Gliadel wafer arm, %
288 2.3 % 2.8 % 1.2 % 14.6 % 0.3 % 11.2 %
AEs, Attenello et al., [46]
placebo arm, %
725 2.1 % 2.2 % 0.7 % 15.7 % 0.3 % 8.9 %
AE adverse events, CE cerebral edema, HA healing abnormalities (including CSF leak and hydrocephalus), IH intracranial hypertension, II intracranial infections
(including abscess, cerebritis, hydrocephitis, and meningitis), ND neurological deficit (including aphasia, change of mental status, epilepsy, and hemiparesis), S
seizures, LE elevated liver enzymes, F fatigue (including fever), GI gastrointestinal disorders (including nausea, vomiting, and constipation), MY myelosuppression
(including anemia, lymphopenia, leukocytopenia, neutropenia, and thrombocytopenia), SK skin and subcutaneous disorders, TE thromboembolic events (including
deep vein thrombosis and pulmonary embolism), UI unidentified
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originally developed. In 2008, Attenello et al. reported
institutional experience in 288 HGG patients (166 newly
diagnosed, 122 recurrent) implanted with Gliadel wafers
compared with 725 patients who underwent craniotomy
without Gliadel implants [46]. For the patients im-
planted with Gliadel wafers versus the patients who
underwent craniotomy without wafers, Attenello et al.
found similar incidences of perioperative infection at the
surgical site (2.8 vs 1.8 %, p = 0.33), CSF leakage (2.8 vs
1.8 %, p = 0.33), meningitis (0.3 vs 0.3 %, p = 1.00), inci-
sional wound healing difficulty (0.7 vs 0.4 %, p = 0.63),
symptomatic malignant edema (2.1 vs 2.3 %, p = 1.00),
seizures at 3 months (14.6 vs 15.7 %, p = 0.65), DVT (6.3
vs 5.2 %, p = 0.53), and pulmonary embolism (4.9 vs
3.7 %, p = 0.41) (Table 5).
More recently, Chaichana et al. from the Johns Hop-
kins School of Medicine retrospectively analyzed all pa-
tients who had undergone resection of GBM from 2007
to 2011, using multivariate proportional hazards regres-
sion analysis to identify factors associated with infection,
including Gliadel wafers [47]. During that time, 401 pa-
tients underwent resection, of whom 21 (5 %) developed
infection at a median 40 days after surgery. The inci-
dence of infection was not higher in patients who re-
ceived Gliadel wafers.
Conclusions
This systematic literature analysis was conducted in the
context of renewed interest in Gliadel wafers following
the disappointing results from recent phase III clinical
trials of other therapies for GBM. In the last two de-
cades, Gliadel wafers and TMZ have been the only
chemotherapy agents for the treatment of newly diag-
nosed GBM that have been confirmed by phase III ran-
domized clinical trials and subsequently approved by the
FDA, and only Gliadel wafers have been approved for
treatment of WHO grade III gliomas.
The rationale for polymeric delivery systems for treat-
ment of HGG, and with that the history of Gliadel wa-
fers, has been extensively reviewed [44]. Moreover, two
meta-analyses have recently affirmed the survival benefit
associated with Gliadel wafers. In one of these meta-
analyses, Xing et al. examined six randomized controlled
studies and four cohort studies for the treatment of
newly diagnosed HGG [48]. In the other of these meta-
analyses, Chowdhary et al. examined 40 studies and 22
abstracts for the treatment of both newly diagnosed
HGG and recurrent GBM [49].
Our findings suggest that when Gliadel wafers and
RT/TMZ are combined, there is a positive additive effect
of improving survival without an increase in toxicity.
The survival benefit appears to be greater than that seen
individually for the separate treatments in their respect-
ive phase III studies compared to placebo wafers with
RT [8–10] or to RT alone [11]. Because improved sur-
vival outcomes can be offered to HGG patients with
agents that are FDA-approved and recommended by
guidelines [14, 15, 50], these therapies should be applied
to maximal advantage when access is not available to a
well-designed rational clinical trial. Moreover, exposure
to these local therapies should not exclude patients from
clinical trial enrollment but should instead be used as
stratification factors for subgroup analyses.
Larger prospective trials of Gliadel plus RT/TMZ are
required for definitive prospective analysis of efficacy
and safety and identification of patients who might bene-
fit most from this sequential combination of treatments.
Our review is hypothesis-generating and supports con-
ducting a phase III clinical trial to compare the RT/
TMZ regimen alone versus the multimodal Gliadel plus
RT/TMZ regimen. In the meantime, two large prospect-
ive registries now underway involving the use of Gliadel
wafers for newly diagnosed HGG—one in Japan with
250 patients (NCT02300506), the other in the USA en-
rolling 500 patients—could confirm and extend the find-
ings reported in the current systematic review.
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